Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.

Frontiers in immunology - 1 Jan 2021

Sloas Christopher, Gill Saar, Klichinsky Michael

Abstract excerpt

Cellular immunotherapies represent a promising approach for the treatment of cancer. Engineered adoptive cell therapies redirect and augment a leukocyte's inherent ability to mount an immune response by introducing novel anti-tumor capabilities and targeting moieties. A prominent example of this approach is the use of T cells engineered to express chimeric antigen receptors (CARs), which have demonstrated...

Topics

Join the communities discussing this publication.

Macrophages
Genetic Therapy
Immunotherapy, Adoptive
Monocytes
Neoplasms
Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, Chimeric Antigen

Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34899748
DOI: 10.3389/fimmu.2021.783305
PMCID: PMC8652144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.PMID 34899748Read ↗

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapySemantic proximity Read ↗

Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity Read ↗

Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities.Semantic proximity Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity Read ↗

Chimeric antigen receptors that trigger phagocytosisSemantic proximity Read ↗

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.Semantic proximity Read ↗

CAR-MACROPHAGES ACTIVATE ANTI TUMOR T CELLS IN THE ABSENCE OF PHAGOCYTOSISSemantic proximity Read ↗

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.Semantic proximity Read ↗

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advancesSemantic proximity Read ↗

A Novel Chimeric Antigen Receptor (CAR) - Strategy to Target EGFR<sup>VIII</sup>-Mutated Glioblastoma Cells via MacrophagesSemantic proximity Read ↗

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFRVIII-mutated glioblastoma cells via macrophages.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.